DURHAM, N.C. — Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ATSN-101, the company’s investigational gene therapy being evaluated in...
Latest News
DURHAM, N.C. — Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, this week presented data from three studies at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Denver, CO. The presentations included 12-month...
DURHAM, N.C. — Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that the independent Data Monitoring Committee (DMC) for the Phase 1/2/3 LIGHTHOUSE Trial evaluating ATSN-201 for the treatment of X-linked retinoschisis (XLRS) has completed its review...
A cross-sectional study found that caregivers of patients with ovarian cancer were experiencing symptoms of depression and anxiety which were affected by attachment avoidance. These findings were published in Current Oncology. Caregivers are an important component of successful cancer treatment, as they ensure treatment adherence as well as provide much needed...
Los Angeles, Calif. – A team of UCLA Health Jonsson Comprehensive Cancer Center investigators has shown the combination of a short course of powerful and intense hormonal therapy with targeted radiation is safe and effective in treating people with prostate cancer that has come back and has spread to other parts...
SAN DIEGO – aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Andrea Wilson as a patient advisor to the company. Ms. Wilson, a sarcoidosis patient and advocate, co-founded the Foundation for...
SAN DIEGO, Calif. — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the path forward for its lead therapeutic candidate, efzofitimod, in pulmonary sarcoidosis, a major form...
SAN DIEGO – aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the last patient has completed their last visit in the company’s Phase 1b/2a clinical trial of its lead therapeutic candidate, ATYR1923, in...
SAN DIEGO – aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced positive results from its Phase 1b/2a double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923, in 37 patients with pulmonary sarcoidosis,...
SAN DIEGO, Calif. — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s meeting request to...